Home News

ROVI completes the manufacture of the first batches of Moderna vaccine

Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the research, development and marketing of biological specialties and a manufacturer with a high degree of technological

Wed, 13/01/2021 - 17:03 0 min
Download related document
No votes yet
 
Related
2025 results press release
Total revenue in 2025 was 756.1 million euros, a 1% decrease on 2024. Operating revenue in 2025 was 743.5 million euros, a 3% decrease...
4 min
25/02/2026
ROVI releases the press release in relation to the signing of the definitive...
In compliance with the disclosure obligations set forth in Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment...
1 min
18/11/2025
First nine months of 2025 results press release
​Operating revenue in the first nine months of 2025 was 525.1 million euros, a 7% decrease on the first nine months of 2024, mainly due...
4 min
06/11/2025